Please try another search
For the fiscal year ended 31 December 2009, Shanrong Biotechnology Corp revenues increased 91% to $1.3M. Net loss increased 87% to $5.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Share-based compensation - Stock options increase from $86K to $3.4M (expense), Other income decrease of 47% to $1K (income).
Period Ending: | Dec 31, 2009 | Sep 30, 2009 | Jun 30, 2009 | Mar 31, 2009 |
---|---|---|---|---|
Total Revenue | 0.11 | 0.13 | 0.69 | 0.4 |
Gross Profit | ||||
Operating Income | -3.98 | 0.23 | -0.36 | -0.69 |
Net Income | -4.07 | 0.18 | -0.45 | -0.74 |
Period Ending: | Dec 31, 2009 | Sep 30, 2009 | Jun 30, 2009 | Mar 31, 2009 |
---|---|---|---|---|
Total Assets | 0.19 | 0.22 | 0.39 | 0.5 |
Total Liabilities | 4.17 | 4.11 | 4.46 | 4.62 |
Total Equity | -3.98 | -3.89 | -4.07 | -4.12 |
Period Ending: | Dec 31, 2009 | Sep 30, 2009 | Jun 30, 2009 | Mar 31, 2009 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -0.79 | -0.45 | -0.32 | -0.11 |
Cash From Investing Activities | 0 | -0 | 0 | |
Cash From Financing Activities | 0.76 | 0.4 | 0.27 | 0.23 |
Net Change in Cash | -0.03 | -0.05 | -0.05 | 0.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review